The trial protocol was approved by the Madrid Region Clinical Research Ethics Committee ( Comit tico de Investigacin Clnica Regional de la Comunidad de Madrid ) on February 8 th 2011, and has been registered with ClinicalTrials.gov number NCT 01476007, and under EUDRACT number 2010-024129-20 [Oral Versus Intramuscular Cobalamin to treat Cobalamin Deficiency: Noninferiority randomised controlled trial, pragmatic and multi-center in the primary healthcare setting (OB12 project)]
[DOI] [PMC free article] [PubMed] [Google Scholar] 336.Azam S., Jakaria M., Kim I.S., Kim J., Haque M.E., Choi D.K
GSH is used as a reducing substrate to promote the transformation of lipid peroxidation products into hydroxyl compounds, preventing ferroptosis in cells and protecting the structure and function of cell membranes from interference and damage (71)
doi: 10.2147/DDDT.S356307 55 LeishmanSAljadeedNMQianLCockcroftSBehmoarasJAnandPK
However, it would be intriguing to determine if selenoprotein status correlated with monocyte CD16 expression
